2024
Classification and Risk Factors for Surgical Site Infections in Radical Cystectomy: A 16-Year Analysis
Lokeshwar S, Choksi A, Smani S, Ip K, Javier-DesLoges J, Rahman S, Leapman M, Martin T, Hesse D. Classification and Risk Factors for Surgical Site Infections in Radical Cystectomy: A 16-Year Analysis. Surgical Infections 2024, 25: 580-585. PMID: 38959160, DOI: 10.1089/sur.2024.107.Peer-Reviewed Original ResearchSurgical site infectionBody mass indexRadical cystectomyCenters for Disease Control and PreventionIndependent risk factorLength of stayRisk factorsAntibiotic agentsSite infectionCenters for Disease Control and Prevention classificationRisk factors of surgical site infectionFactors associated with surgical site infectionFactors of surgical site infectionPredictive of surgical site infectionDeep incision surgical site infectionSurgical site infection predictorsOdds ratioTreatment of surgical site infectionsDeep surgical site infectionPeri-operative characteristicsPeri-operative morbidityCharlson Comorbidity IndexLogistic regression analysisSuperficial incisionalDisease Control and Prevention
2022
Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder
Rahman S, Lokeshwar S, Syed J, Javier-Desloges J, Press B, Choksi A, Rajwa P, Pradere B, Ploussard G, Kim J, Monaghan T, Renzulli J, Shariat S, Leapman M. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder. Urologic Oncology Seminars And Original Investigations 2022, 41: 107.e1-107.e8. PMID: 36481253, DOI: 10.1016/j.urolonc.2022.09.008.Peer-Reviewed Original ResearchConceptsVariant urothelial carcinomaNeoadjuvant chemotherapySubset of patientsUrothelial carcinomaOverall survivalPathologic responseRadical cystectomyNAC useClinical stage II diseaseHospital-based registry studyNeoadjuvant platinum-based chemotherapyPathologic lymph node positivityCox proportional hazards modelNational Cancer DatabaseStage II diseaseLymph node positivityPathologic complete responsePlatinum-based chemotherapyKaplan-Meier analysisMultivariable logistic regressionAnalysis of patientsBladder urothelial carcinomaProportional hazards modelCT2 diseasePathologic upstaging
2020
PT414 Similar survival outcomes among chemoradiation and neoadjuvant chemotherapy with radical cystectomy for small cell bladder cancer
Abello A, Renzulli J, Park H, Leapman M, Kenney P. PT414 Similar survival outcomes among chemoradiation and neoadjuvant chemotherapy with radical cystectomy for small cell bladder cancer. European Urology Open Science 2020, 19: e2283. DOI: 10.1016/s2666-1683(20)34148-3.Peer-Reviewed Original Research
2019
National trends and pathologic outcomes of neoadjuvant chemotherapy among patients with micropapillary variant urothelial carcinoma of the bladder.
Javier-Desloges J, Abello A, Syed J, Leapman M. National trends and pathologic outcomes of neoadjuvant chemotherapy among patients with micropapillary variant urothelial carcinoma of the bladder. Journal Of Clinical Oncology 2019, 37: 477-477. DOI: 10.1200/jco.2019.37.7_suppl.477.Peer-Reviewed Original ResearchUse of NACUrothelial cell carcinomaReceipt of NACNeoadjuvant chemotherapyMicropapillary variantPathologic responseEntire cohortCell carcinomaClinical stage II diseasePropensity scoreVariant urothelial carcinomaNational Cancer DatabaseStage II diseaseComplete pathologic responsePathologic complete responseAggressive clinical behaviorLogistic regression modelsCT2 diseasePT0 rateComplete responsePathologic characteristicsRadical cystectomyDistant metastasisHistological diagnosisNAC useUrologic malignancies: A comparison of outcomes after index surgery between academic and community hospitals.
Syed J, Abello A, Javier-Desloges J, Leapman M, Kenney P. Urologic malignancies: A comparison of outcomes after index surgery between academic and community hospitals. Journal Of Clinical Oncology 2019, 37: 489-489. DOI: 10.1200/jco.2019.37.7_suppl.489.Peer-Reviewed Original ResearchVizient clinical databaseCase mix indexAcademic hospitalCommunity hospitalRadical prostatectomyReadmission ratesPartial cystectomyRadical cystectomyUrologic malignanciesPartial nephrectomyClinical databaseRate of hospitalDirect costsLength of stayICD-10 codesMean direct costComparison of outcomesPart of treatmentSignificant differencesStudent's t-testIndex admissionIndex surgeryRadical nephroureterectomyPatient demographicsSurgical treatment
2017
Impact of histologic subtype on bladder cancer outcome.
Washington S, Sanford T, Leapman M, Meng M, Porten S. Impact of histologic subtype on bladder cancer outcome. Journal Of Clinical Oncology 2017, 35: 391-391. DOI: 10.1200/jco.2017.35.6_suppl.391.Peer-Reviewed Original ResearchNational Cancer DatabaseVariant histologySmall cell carcinomaSquamous cell carcinomaBladder cancer outcomesCell carcinomaUrothelial carcinomaHazard ratioOverall survivalIndependent predictorsRadical cystectomyCancer outcomesBlack ethnicityBladder cancerMean age 67 yearsU.S. population-based cohortCommon variant histologyNon-urothelial histologyMultivariable Cox regressionSurgical margin statusAge 67 yearsPathologic T stageWorse overall survivalHistory of chemotherapyPopulation-based cohort